Major depressive disorder (MDD) was previously hypothesized to be a disease of
monoamine deficiency in which low levels of monoamines in the synaptic cleft were …

The emerging therapeutic efficacy of ketamine and classical psychedelics for depression
has inspired tremendous interest in the underlying neurobiological mechanisms. We review …

The microbial ecosystem that inhabits the gastrointestinal tract of all mammals—the gut
microbiota—has been in a symbiotic relationship with its hosts over many millennia. Thanks …

Major depression is one of the leading causes of disability, morbidity, and mortality
worldwide. The brain–gut axis functions are disturbed, revealed by a dysfunction of the …

Depression and anxiety disorders are the two most prevalent psychiatric diseases that affect
hundreds of millions of individuals worldwide. Understanding the etiology and related …

Air pollution is a risk factor for cardiovascular and respiratory morbidity and mortality. A
growing literature also links exposure to diverse air pollutants (eg, nanoparticles, particulate …

Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …

Ketamine, a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptor, displays
a fast antidepressant activity in treatment-resistant depression and in rodent models of …

The discovery of ketamine as a rapid-acting antidepressant spurred significant research to
understand its underlying mechanisms of action and to identify other novel compounds that …

Depression is the most prevalent and debilitating mental disorder that affects a substantial
number of people globally, hindering all aspects of their lives and leading to a high number …